




RealRate

# PHARMACEUTICAL 2020

## Matinas BioPharma Holdings Inc. Rank 95 of 358

MATINAS  
BIOPHARMA





RealRate

# PHARMACEUTICAL 2020

## Matinas BioPharma Holdings Inc. Rank 95 of 358

MATINAS  
BIOPHARMA

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 130% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	29,923
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	3,097
Liabilities, Non-Current	4,091
Other Assets	7,232
Other Compr. Net Income	-0.88
Other Expenses	0
Other Liabilities	0
Other Net Income	1,548
Other Revenues	90
Property and Equipment	1,749
Research and Development	11,235
Selling, General and Administrative Expense	7,776

Output Variable	Value in 1000 USD
Assets	40,240
Liabilities	7,189
Expenses	19,011
Revenues	90
Stockholders Equity	33,052
Net Income	-17,373
Comprehensive Net Income	-17,373
Economic Capital Ratio	166%